Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation (Q36005008)

11 August 2017

1 reference

title

Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation (English)

1 reference

11 August 2017

1 reference

1 reference

Olof Selroos

1

1 reference

11 August 2017

Staffan Edsbäcker

series ordinal

2

1 reference

11 August 2017

Christer Hultquist

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

41

1 reference

11 August 2017

issue

8

1 reference

11 August 2017

page(s)

771-790

1 reference

Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Failure of once daily inhaled corticosteroid treatment to control chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

A Comparison of the Effects of bid and qid Dosing on Compliance with Inhaled Flunisolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Daily regimen and compliance with treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

The devil is in the details

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

My initiation into respiratory physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Efficacy and safety of inhaled corticosteroids. New developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Airways inflammation in nocturnal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Inhaled corticosteroids for asthma: common clinical quandaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Once-daily inhaled corticosteroids for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

Rationale for once-daily therapy in asthma: compliance issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-200038344

21 January 2018

Identifiers

DOI

10.1081/JAS-200038344

1 reference

11 August 2017

1 reference